Angelini Ventures invests in the development of radiopharmaceuticals and copper-based therapies for the treatment of various oncological diseases. The venture capital fund, which is part of Angelini Industries, co-led an €84 million Series B financing round in Nuclidium. , a clinical-stage radiopharmaceutical company developing a theranostic platform using copper isotopes (Cu-61 and Cu-67) for oncology applications.
The investment, led by Angelini Ventures, Kurma Growth Opportunities Fund, Wellington Partners and Neva, also includes participation from Deep Tech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.Bank and Highlight Capital, in addition to existing investors.
The investment is aimed at supporting the clinical development of the copper isotope therapeutic pipeline, in particular Nuclidium’s copper-61 and copper-67 in various oncological indications. At the same time, the company aims to expand its production and therapeutic capacity through a global network.
Nuclidium’s innovative platform combines molecules that specifically recognise tumours with two special forms of copper: one, called Cu-61, is used to obtain more accurate diagnostic images, while the other, Cu-67, is used to treat tumours.
Thanks to this combination, Nuclidium’s technology aims to overcome some of the limitations of current therapies, such as suboptimal efficacy and difficulties associated with the production of radiopharmaceuticals.
Early results from clinical trials show that the imaging system developed by Nuclidium is better at detecting tumour lesions than currently available tools, providing clearer and more detailed images. The initial data, recently presented by Gary Ulaner at the SNMMI 2025 annual conference, also indicate that the diagnostic product has a good safety profile and could offer superior performance compared to the imaging techniques used today in PET.
Furthermore, initial data on the therapeutic use of the two main compounds are promising: they show a strong ability to concentrate treatment in tumour areas, particularly in metastatic prostate cancer, neuroendocrine tumours and breast cancer. With its products, Nuclidium promises significant potential in both the diagnosis and treatment of tumours, with the prospect of extending access to targeted therapies to a wider population of patients, including in oncology areas where current options are limited.
“Nuclidium is entering the next clinical phases with its main compounds for the diagnosis and treatment of metastatic prostate cancer, neuroendocrine tumours and breast cancer,” says Leila Jaafar, PhD, CEO and co-founder of Nuclidium, in a statement. “Our copper-based radiotheranostics have been developed for use in healthcare delivery and waste management without being critical elements in hospital workflows, thus making this type of therapy more accessible globally. Our innovative, next-generation copper isotope platform also allows us to rapidly develop new targets for a wider range of cancers, particularly those of great relevance to women’s health.”
Thanks to this funding, Nuclidium will continue to expand its global production and manufacturing network for diagnostics and therapeutics, grow its international team, and strengthen strategic collaborations with hospitals and academic centres, initially focusing on Europe and North America.
With the closing of the financing round, Regina Hodits, managing director of Angelini Ventures, joins the Nuclidium Board of Directors, alongside Daniel Parera, partner at Kurma Partners, and Liliana Nordbakk, life science partner at NEVA.
“We are delighted to have co-led this round of financing in Nuclidium alongside other high-profile European investors. At Angelini Ventures, we continue to identify and support companies that pursue scientifically differentiated opportunities with a clear path to addressing unmet medical needs,” said Regina Hodits, managing director of Angelini Ventures (pictured). “We look for dynamic founders and contexts where our investment, combined with active involvement, can help fully realise therapeutic potential.”
ALL RIGHTS RESERVED ©